A Phase 3 interventional study of Tradipitant and Placebo in Idiopathic Gastroparesis, Diabetic Gastroparesis and Gastroparesis, sponsored by Vanda Pharmaceuticals. Completed at 36 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one has the largest enrollment of the 136 interventional ones that give a count, is one of 17 that started in 2019, is one of 12 in phase 3, and was the 109th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 17 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 979 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 4 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Capsule
Drug: Tradipitant
Oral Capsule
Drug: Placebo
Oral Capsule
Drug: Open Label Tradipitant
BID
BID
BID
Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the biweekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.
Time frame: 12 weeks
Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Total Score Using MMRM Model ITT Population
The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.
Time frame: 12 Weeks
Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model ITT Population
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as biweekly average post value minus baseline value.
Time frame: 12 Weeks
Change From Baseline in Overall Patient Benefit Scale (OPBS) ITT Population
The Overall Patient Benefit Scale (OPBS) is a weighted average of the recoded symptom improvement score of the five PRCGS items. The PRCGS data are recoded as follows: 3 - very much improved, 2 - much improved, 1 - minimally improved, 0 - no change or worse. The OPBS ranges from 0 to 3, with higher values indicating a better outcome.
Time frame: 12 Weeks
| Milestone | Tradipitant | Placebo | Open Label Tradipitant |
|---|---|---|---|
| Started | 102 | 99 | 778 |
| Completed | 83 | 88 | 643 |
| Not completed | 19 | 11 | 135 |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the biweekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.
| score on a scale | Tradipitant | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population | -1.55 (-1.82 to -1.29) | -1.49 (-1.76 to -1.23) |
The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.
| score on a scale | Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Total Score Using MMRM Model ITT Population | -1.48 (-1.72 to -1.23) | -1.39 (-1.63 to -1.15) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as biweekly average post value minus baseline value.
| Percentage of Days | Tradipitant | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model ITT Population | 20.70 (13.08 to 28.32) | 28.96 (21.37 to 36.55) |
The Overall Patient Benefit Scale (OPBS) is a weighted average of the recoded symptom improvement score of the five PRCGS items. The PRCGS data are recoded as follows: 3 - very much improved, 2 - much improved, 1 - minimally improved, 0 - no change or worse. The OPBS ranges from 0 to 3, with higher values indicating a better outcome.
| score on a scale | Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in Overall Patient Benefit Scale (OPBS) ITT Population | 1.55 (1.33 to 1.78) | 1.39 (1.17 to 1.61) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the biweekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.
| score on a scale | High PK Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model PK Population | -1.89 (-2.26 to -1.53) | -1.49 (-1.77 to -1.22) |
The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.
| score on an scale | High PK Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in GCSI Total Score Using MMRM Model PK Population | -1.61 (-1.95 to -1.27) | -1.39 (-1.64 to -1.13) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as biweekly average post value minus baseline value.
| Percentage of Days | High PK Tradipitant | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model PK Population | 30.31 (19.53 to 41.10) | 29.11 (21.05 to 37.17) |
The Overall Patient Benefit Scale (OPBS) is a weighted average of the recoded symptom improvement score of the five PRCGS items. The PRCGS data are recoded as follows: 3 - very much improved, 2 - much improved, 1 - minimally improved, 0 - no change or worse. The OPBS ranges from 0 to 3, with higher values indicating a better outcome.
| score on a scale | High PK Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in Overall Patient Benefit Scale (OPBS) PK Population | 1.70 (1.3944 to 2.0151) | 1.40 (1.1651 to 1.6285) |
Collected over All Adverse Events (AEs) were collected from the time of the subject's informed consent signature until the end of the subject's study participation. AEs reported or learned up to 7 days after the subject's last study visit were recorded, up to 17 weeks. SAEs reported or learned up to 30 days after last study visit were recorded, up to 20 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tradipitant | 0/102 (0%) | 3/102 (2.9%) | 48/102 (47.1%) |
| Placebo | 0/99 (0%) | 2/99 (2%) | 25/99 (25.3%) |
| Open Label Tradipitant | 2/778 (0.3%) | 35/778 (4.5%) | 267/778 (34.3%) |
| Event | Tradipitant | Placebo | Open Label Tradipitant |
|---|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 0/102 | 1/99 | 0/778 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/102 | 1/99 | 0/778 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/102 | 0/99 | 0/778 |
| Myocardial infarctionCardiac disorders | 1/102 | 0/99 | 0/778 |
| Small intestinal obstructionGastrointestinal disorders | 1/102 | 0/99 | 1/778 |
| DiverticulitisInfections and infestations | 0/102 | 0/99 | 3/778 |
| Corona virus infectionInfections and infestations | 0/102 | 0/99 | 2/778 |
| ParaesthesiaNervous system disorders | 0/102 | 0/99 | 2/778 |
| CellulitisInfections and infestations | 0/102 | 0/99 | 2/778 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/102 | 0/99 | 2/778 |
| Event | Tradipitant | Placebo | Open Label Tradipitant |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 10/102 | 2/99 | 37/778 |
| Urinary tract infectionInfections and infestations | 4/102 | 4/99 | 20/778 |
| HeadacheNervous system disorders | 4/102 | 2/99 | 22/778 |
| ConstipationGastrointestinal disorders | 1/102 | 3/99 | 13/778 |
| DizzinessNervous system disorders | 3/102 | 3/99 | 17/778 |
| NauseaGastrointestinal disorders | 2/102 | 2/99 | 23/778 |
| FatigueGeneral disorders | 2/102 | 1/99 | 23/778 |
| SinusitisInfections and infestations | 3/102 | 1/99 | 8/778 |
| PneumoniaInfections and infestations | 3/102 | 0/99 | 4/778 |
| Corona virus infectionInfections and infestations | 1/102 | 0/99 | 21/778 |
| Age, Continuous(years) | Tradipitant | Placebo | Open Label Tradipitant | Total |
|---|---|---|---|---|
| Mean | 49.5 ± 13.97 | 48.8 ± 11.99 | 50.5 ± 12.84 | 50.23 ± 12.88 |
| Sex: Female, Male(Participants) | Tradipitant | Placebo | Open Label Tradipitant | Total |
|---|---|---|---|---|
| Female | 77 | 84 | 617 | 778 |
| Male | 25 | 15 | 161 | 201 |
| Ethnicity (NIH/OMB)(Participants) | Tradipitant | Placebo | Open Label Tradipitant | Total |
|---|---|---|---|---|
| Hispanic or Latino | 29 | 22 | 190 | 241 |
| Not Hispanic or Latino | 73 | 75 | 580 | 728 |
| Unknown or Not Reported | 0 | 2 | 8 | 10 |
| Race/Ethnicity, Customized(Participants) | Tradipitant | Placebo | Open Label Tradipitant | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 14 | 15 |
| Asian | 0 | 1 | 7 | 8 |
| Black or African American | 9 | 16 | 155 | 180 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 2 |
| White | 90 | 81 | 589 | 760 |
| Other | 2 | 1 | 11 | 14 |
| Region of Enrollment(participants) | Tradipitant | Placebo | Open Label Tradipitant | Total |
|---|---|---|---|---|
| United States | 102 | 99 | 778 | 979 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Feb 2025, 66 months.
Results were first posted in Sep 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant